News | December 07, 2022
Fraunhofer IZI Selects Lonza’s MODA-ES Solution to Digitalize Manufacturing Operations
GMP-compliant documentation of all manufacturing steps for cell and gene therapies
GMP-compliant documentation of all manufacturing steps for cell and gene therapies
The service includes full fertility care benefits, including egg and embryo freezing options to employees
Expanded capacity in Nansha, China will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
New Lexington, Massachusetts facility to provide customer education and collaboration opportunities
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints
Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)
Subscribe To Our Newsletter & Stay Updated
